¼¼°èÀÇ In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ ½ÃÀå
In-Vitro and In-Vivo Micro Electrode Arrays
»óǰÄÚµå : 1792739
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 549 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3,680¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3,030¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 3.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3,680¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¸ÖƼ À£ MEA À¯ÇüÀº CAGR 4.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 2,460¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Ì±Û À£ MEA À¯Çü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 830¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ ½ÃÀåÀº 2024³â¿¡ 830¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 730¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.2%¿Í 2.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹À̰¡ ½Å°æ°úÇÐ ¹× »ý¹° ÀÇÇÐ ¿¬±¸ ¹ßÀü¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

MEA(¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ)´Â ½Å°æ ¹× ¼¼Æ÷ Ȱµ¿ÀÇ °íÇØ»óµµ ±â·Ï°ú ÀÚ±ØÀ» °¡´ÉÇϰÔÇÔÀ¸·Î½á Çö´ë ½Å°æ°úÇÐ ¹× »ý¹° ÀÇÇÐ ¿¬±¸¿¡ Çõ½ÅÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡´Â »ýü Á¶Á÷°ú ÀüÀÚ ½Ã½ºÅÛ °£ÀÇ °­·ÂÇÑ ÀÎÅÍÆäÀ̽º¸¦ Á¦°øÇÏ¿© ¿¬±¸ÀÚµéÀÌ º¹ÀâÇÑ ½Å°æ ȸ·Î¸¦ ÇØµ¶Çϰí, Áúº´ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϰí, ¾à¸®ÇÐÀû ¹ÝÀÀÀ» ½Ç½Ã°£À¸·Î Å×½ºÆ®ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. In vitro MEA´Â ½Ã³À½º Àü´Þ, ½Å°æµ¶¼º, ¾àÈ¿ µîÀÇ Çö»óÀ» ¿¬±¸Çϱâ À§ÇØ ¼¼Æ÷¹è¾ç, ±â°üÇü ½½¶óÀ̽º, ºê·¹ÀÎ ¿Â Ĩ ¸ðµ¨¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, Àüü µ¿¹° ½ÇÇè¿¡ ´ëÇÑ À±¸®ÀûÀ̰í È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, in vivo MEA´Â ÀüÀÓ»ó ¹× ÀÓ»ó ¸ðµ¨¿¡¼­ ³ú Ȱµ¿ÀÇ ¸¸¼º ÀÌ½Ä ¹× ½Ç½Ã°£ ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀ̸ç, °£Áú, ÆÄŲ½¼º´, ô¼ö ¼Õ»ó µîÀÇ º´Å»ý¸®¿¡ ´ëÇÑ Áö½ÄÀ» Á¦°øÇÕ´Ï´Ù. ¹Ð¸®ÃÊ ´ÜÀ§ÀÇ Á¤¹Ðµµ¿Í ¼¼Æ÷ ¼öÁØÀÇ ÇØ»óµµ·Î Àü±âÀû ÆÐÅÏÀ» °üÂûÇÒ ¼ö ÀÖ´Â MEA´Â ½Å°æ°èÀÇ ¿ªµ¿¼ºÀ» ÀÌÇØÇϰí, ³ú ¿µ¿ªÀ» ¸ÅÇÎÇϰí, ½Å°æ Àΰø Àå±âÀÇ °³¹ßÀ» °³¼±ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Á¤¹ÐÀÇ·á°¡ ź·ÂÀ» ¹Þ°í ÀÖ´Â °¡¿îµ¥, MEA´Â À¯ÀüÀÚ Ä¡·á¿Í ½Å°æ ÀÎÅÍÆäÀ̽º ±â¼úÀÇ °ËÁõÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ±× ¹ü¿ë¼ºÀº ½Å°æ»ý¹°ÇÐ, ¾à¸®ÇÐ, Á¶Á÷°øÇÐ, ³ú-ÄÄÇ»ÅÍ ÀÎÅÍÆäÀ̽º ¿¬±¸ µî ´Ù¾çÇÑ ºÐ¾ß¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. »ý¸í°úÇÐ ºÐ¾ß¿¡¼­ °³ÀÎÈ­ ¹× µ¥ÀÌÅÍ ±â¹Ý Á¢±Ù¹ýÀÇ ºÎ»óÀ¸·Î ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ´Â ¼¼Æ÷ Ä¿¹Â´ÏÄÉÀ̼ǰú ½Å°æ»ý¸®ÇÐÀÇ º¹À⼺À» ¹àÇô³»´Â ±âÃÊÀûÀÎ µµ±¸·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô MEAÀÇ ¼º´É°ú ÀÀ¿ëÀ» Çâ»ó½Ã۴°¡?

Àç·á °úÇÐ, ¹Ì¼¼ °¡°ø ±â¼ú ¹× °è»ê ó¸®ÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌÀÇ ¿ë·®ÀÌ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÃֽŠMEA´Â Æú¸®À̵̹å, ÆÄ¸±·», ±×·¡ÇÉ µî ÃʹÚÇü, À¯¿¬ÇÑ ±âÆÇÀ¸·Î Á¦ÀÛµÇ¾î ¸¸¼º ÀÌ½Ä ½Ã ¿ì¼öÇÑ »ýüÀûÇÕ¼º°ú ±â°èÀû ÀûÇÕ¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ À¯¿¬ÇÑ ÀåÄ¡´Â ¾ÈÁ¤ÀûÀ̰í Àå±âÀûÀÎ ±â·ÏÀ» À¯ÁöÇϸ鼭 Á¶Á÷ ¼Õ»ó°ú ¿°ÁõÀ» ÁÙ¿©ÁÝ´Ï´Ù. Àü±ØÀÇ ¼ÒÇüÈ­ ¹× °í¹ÐµµÈ­ Çõ½ÅÀº ¼öõ °³ÀÇ ºÎÀ§¿¡¼­ µ¿½Ã¿¡ ±â·ÏÇÒ ¼ö ÀÖ´Â ³ôÀº ä³Î ¼öÀÇ MEA¸¦ »ý¼ºÇÏ¿© Àüü ½Å°æ¸Á¿¡ °ÉÃÄ Á¾ÇÕÀûÀÎ °ø°£Àû ¹× ½Ã°£Àû ÇØ»óµµ¸¦ Á¦°øÇÕ´Ï´Ù. ±¤¼¾¼­, ¹Ì¼¼À¯Ã¼°øÇÐ, ¾à¹°Àü´Þ ºÎǰ°úÀÇ ÅëÇÕÀ» ÅëÇØ Àü±â»ý¸®ÇÐ, À̹Ì¡, ±¹¼Ò È­ÇÐÀû ÀÚ±ØÀ» µ¿½Ã¿¡ ¼öÇàÇÒ ¼ö ÀÖ´Â ´Ù±â´É Ç÷§ÆûÀÇ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¼ÒÇÁÆ®¿þ¾î Ãø¸é¿¡¼­´Â ±â°è ÇнÀ ¾Ë°í¸®Áò°ú °í±Þ ½ÅÈ£ ó¸® µµ±¸¸¦ ÅëÇØ ½Å°æ Ȱµ¿ÀÇ ½Ç½Ã°£ ÇØµ¶ÀÌ °¡´ÉÇÏ¿© º¸´Ù Á¤È®ÇÑ ÇØ¼®°ú µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÀÚµ¿È­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹«¼± MEA ½Ã½ºÅÛÀº µ¿¹° ½ÇÇèÀ» Áö¿øÇϰí, ÀÚ¿¬½º·¯¿î ÇൿÀ» À¯ÁöÇϸç, ½ºÆ®·¹½º¿Í °ü·ÃµÈ Àΰø¹°À» ÁÙÀ̱â À§ÇØ µîÀåÇϰí ÀÖ½À´Ï´Ù. Àü·Â È¿À²°ú µ¥ÀÌÅÍ Àü¼Û ¼Óµµµµ Çâ»óµÇ¾î ¿¬¼Ó ¸ð´ÏÅ͸µ ¹× Æó¼â ·çÇÁ ÀÚ±Ø ÆÐ·¯´ÙÀÓÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ¸·Î MEAÀÇ ¿ëµµ´Â ±âÁ¸ÀÇ ½Å°æ°úÇп¡ ±¹ÇѵÇÁö ¾Ê°í ½ÉÀå Àü±â»ý¸®ÇÐ, ¿À°¡³ëÀÌµå °³¹ß, ¹ÙÀÌ¿ÀÀüÀÚ ÀÇ·á ºÐ¾ß·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. MEA ±â¼úÀº Áö¼ÓÀûÀ¸·Î ÁøÈ­Çϰí ÀÖÀ¸¸ç, ±× Á¤È®¼º, ½Å·Ú¼º, ÀûÀÀ¼ºÀ¸·Î ÀÎÇØ Â÷¼¼´ë ¹ÙÀÌ¿À ÀÏ·ºÆ®·Î´Ð½º ¹× ½Å°æ°øÇÐ ¼Ö·ç¼ÇÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¿¬±¸ ¸ñÀû°ú »ý¹°ÇÐÀû ¸ðµ¨Àº MEAÀÇ ¼³°è¿Í »ç¿ë¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?

¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌÀÇ ¼³°è¿Í ¹èÄ¡´Â ƯÁ¤ ¿¬±¸ ¸ñÀû°ú ¿¬±¸ ´ë»óÀÇ »ý¹°ÇÐÀû ¸ðµ¨¿¡ µû¶ó Å©°Ô ´Þ¶óÁö±â ¶§¹®¿¡ °¢°¢ÀÇ ¿ëµµ¿¡ ¸Â´Â Á¢±ÙÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¼¼Æ÷¹è¾ç ¹× ³ú ½½¶óÀ̽º¿¡ »ç¿ëµÇ´Â in-vitro MEA´Â ÀϹÝÀûÀ¸·Î ±¤ÇÐ À̹Ì¡°ú ÆÐÄ¡ Ŭ·¥ÇÎÀ» µ¿½Ã¿¡ ½±°Ô ÇÒ ¼ö ÀÖµµ·Ï Åõ¸íÇÑ ±âÆÇÀ» °®Ãá Æò¸é ±¸¼ºÀ» Ư¡À¸·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ¾à¹° È­ÇÕ¹°ÀÇ °í󸮷® ½ºÅ©¸®´×, ½Å°æ ¹ß´Þ ¸ðµ¨¸µ, ÅëÁ¦µÈ ȯ°æ¿¡¼­ÀÇ ½Å°æ µ¶¼º È¿°ú Æò°¡¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ¹Ý´ë·Î »ýü ³» MEA´Â »ì¾ÆÀÖ´Â Á¶Á÷¿¡ »ðÀÔÇϱâ À§ÇØ ¼³°èµÇ¾úÀ¸¸ç, ¸é¿ª¹ÝÀÀÀ» ÃÖ¼ÒÈ­Çϸ鼭 º¹ÀâÇÑ ÇØºÎÇÐÀû ±¸Á¶¸¦ Ž»öÇØ¾ß ÇÕ´Ï´Ù. ³ú ½ÉºÎ ±¸Á¶¸¦ ´ë»óÀ¸·Î ÇÏ´Â ´ÜÀÏ »ýÅ© ÇÁ·ÎºêºÎÅÍ ´ë³ú ÇÇÁúÃþ¿¡ °ÉÄ£ ´ÙÁß »ýÅ© ¾î·¹À̱îÁö ´Ù¾çÇÑ ¼³°è°¡ ÀÖ¾î ¿¬±¸ÀÚµéÀº ´Ù¾çÇÑ ½Å°æ Áý´ÜÀ» µ¿½Ã¿¡ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÚÀ¯·Ó°Ô ¿òÁ÷ÀÌ´Â µ¿¹°À» ´ë»óÀ¸·Î ÇÏ´Â ¾ÖÇø®ÄÉÀ̼ǿ¡¼­ MEA´Â °íÃæ½Çµµ ±â·ÏÀ» À¯ÁöÇϸ鼭 ½Åü Ȱµ¿À» °ßµô ¼ö ÀÖÀ» ¸¸Å­ °¡º±°í °ß°íÇØ¾ß ÇÕ´Ï´Ù. ¸¸¼º ÀÓÇöõÆ® ¿¬±¸¿¡¼­´Â Àå±â°£¿¡ °ÉÃÄ ½ÅÈ£ÀÇ ¹«°á¼ºÀ» º¸ÀåÇϱâ À§ÇØ ¾ÈÁ¤ÀûÀÎ Àü±Ø Àç·á¿Í º¸È£ ÄÚÆÃÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¿îµ¿ Á¦¾î ¹× ¹ßÀÛ È°µ¿À» ¿¬±¸ÇÏ´Â ¿¬±¸ÀÚµéÀº MEA¸¦ Çൿ ÃßÀû ½Ã½ºÅÛ°ú ÅëÇÕÇÏ¿© Àü±â ½ÅÈ£¿Í ½ÇÁ¦ ÇൿÀ» ¿¬°ü½Ãų ¼ö ÀÖ½À´Ï´Ù. Àç»ýÀÇ·á¿¡¼­´Â Áٱ⼼Æ÷ À¯·¡ ´º·±ÀÌ ¼÷ÁÖ Á¶Á÷ ³»¿¡¼­ ±â´ÉÀûÀ¸·Î ÅëÇյǴ °úÁ¤À» ¸ð´ÏÅ͸µÇϱâ À§ÇØ MEA°¡ »ç¿ëµÇ°í ÀÖÀ¸¸ç, Ä¡·á È¿°ú¸¦ ½Ç½Ã°£À¸·Î °ËÁõÇÒ ¼ö ÀÖ½À´Ï´Ù. Çмú, Á¦¾à ¹× ÀÓ»ó ¿¬±¸¿¡¼­ÀÇ ½ÇÇè ¼³Á¤ÀÇ ´Ù¾ç¼ºÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ Á¶Á÷ À¯Çü, ±Ô¸ð ¹× ºÐ¼® ¿öÅ©Ç÷ο쿡 ÀûÀÀÇÒ ¼ö ÀÖ´Â ¸ðµâ½Ä ¹× ¸ÂÃãÇü MEA Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹ü¿ë¼º°ú ƯÀ̼º¿¡ ´ëÇÑ ÀÌ·¯ÇÑ ¼ö¿ä´Â MEA ¼³°èÀÇ ´ÙÀ½ ±â¼ú Çõ½ÅÀÇ ¹°°áÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ ¼¼°è ½ÃÀå ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

In-Vitro ¹× In-Vivo ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº »ý¹° ÀÇÇÐ ¿¬±¸ ¹× Ä¡·á °³¹ßÀÇ Àü¸ÁÀ» ¹Ù²Ù°í ÀÖ´Â °úÇÐÀû, ÀÓ»óÀû, ±â¼úÀû ¿äÀÎÀÇ °áÇÕÀÔ´Ï´Ù. °¡Àå ¿µÇâ·Â ÀÖ´Â ¿øµ¿·Â Áß Çϳª´Â ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, °£Áú, ´Ù¹ß¼º °æÈ­Áõ°ú °°Àº ½Å°æ Áúȯ ¹× ½Å°æ ÅðÇ༺ ÁúȯÀÇ ¼¼°èÀû ºÎ´ã Áõ°¡·Î, ÷´Ü Áø´Ü µµ±¸¿Í Ä¡·á ¸ð´ÏÅ͸µ ¹æ¹ýÀÌ ½Ã±ÞÈ÷ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. MEA´Â ¼¼Æ÷ ¹× ³×Æ®¿öÅ© ¼öÁØ¿¡¼­ Áúº´ ¸ÞÄ¿´ÏÁòÀ» ¿¬±¸ÇÒ ¼ö ÀÖ´Â µ¶º¸ÀûÀÎ ´É·ÂÀ» Á¦°øÇÏ¿© ½Å¾à Ÿ°Ù ¹× ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ßÀ» °¡¼ÓÈ­ÇÕ´Ï´Ù. ÀÌ¿Í ÇÔ²² ½Å°æº¸Ã¶ ¹× ÀÎÁö±â´É °­È­ ±â¼úÀ» Æ÷ÇÔÇÑ ³ú-±â°è ÀÎÅÍÆäÀ̽º¿¡ ´ëÇÑ ¿¬±¸°¡ ±ÞÁõÇϸ鼭 °íÇØ»óµµ ½Å°æ ±â·Ï µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½Å°æ°úÇÐ ¹× Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ ±â¾÷ÀÇ ÀÚ±Ý Áö¿øÀº ±â´É °ËÁõ ¹× ½Ç½Ã°£ Çǵå¹éÀ» À§ÇØ MEA Ç÷§Æû¿¡ ÀÇÁ¸ÇÏ´Â ¿¬±¸¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. 3D ¼¼Æ÷¹è¾ç, ³ú ¿À°¡³ëÀ̵å, ·¦¿ÂĨ ±â¼úÀÇ ¹ßÀüÀº ¾à¹° Å×½ºÆ® ¹× ¹ß»ý »ý¹°Çп¡¼­ in-vitro MEAÀÇ »õ·Î¿î ÁöÆòÀ» ¿­°í ÀÖ½À´Ï´Ù. Çаè, »ý¸í°øÇÐ ±â¾÷, À§Å¹ ¿¬±¸±â°ü ¸ðµÎ ÀçÇö¼º, È®À强, °í󸮷® µ¥ÀÌÅÍ ¼öÁýÀ» ÇÊ¿ä·Î ÇÏ´Â ¿¬±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±âÁ¸ Àü±â»ý¸®ÇÐÀû ¹æ¹ýº¸´Ù MEA¸¦ ¼±È£Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñµ¿¹°½ÇÇè¹ýÀ» ÁöÁöÇÏ´Â ±ÔÁ¦ ±â·ù´Â MEA°¡ ÀǾàǰ ÆÄÀÌÇÁ¶óÀο¡¼­ À±¸®ÀûÀ̰í È¿À²ÀûÀÎ ´ë¾ÈÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÇ°í, µ¥ÀÌÅÍ Áý¾àÀûÀ̸ç, À±¸®ÀûÀ¸·Î °ÇÀüÇÑ ¿¬±¸ ¹æ¹ýÀÇ ÃßÁøÀÌ °­È­µÊ¿¡ µû¶ó ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌÀÇ ¿ªÇÒÀº Å©°Ô È®´ëµÉ °ÍÀ̸ç, »ý¸í°úÇаú ½Å°æ±â¼úÀÇ ¹Ì·¡¿¡ ÇʼöÀûÀÎ µµ±¸·Î ÀÚ¸®¸Å±èÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

À¯Çü(¸ÖƼ À£ MEA À¯Çü, ½Ì±Û À£ MEA À¯Çü), ±â¼ú(ÀκñÆ®·Î MEA ±â¼ú, Àκñº¸ MEA ±â¼ú), ±¸¼º¿ä¼Ò(Çϵå¿þ¾î ±¸¼º¿ä¼Ò, ¼ÒÇÁÆ®¿þ¾î ±¸¼º¿ä¼Ò), ¿ëµµ(½Å°æ°úÇÐ ¿¬±¸ ¿ëµµ, ½ÉÀå ¿¬±¸ ¿ëµµ, ÀǾàǰ °³¹ß/µ¶¼º ½ÃÇè ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾àȸ»ç&CRO ÃÖÁ¾ ¿ëµµ, Çмú/Á¤ºÎ/±âŸ ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global In-Vitro and In-Vivo Micro Electrode Arrays Market to Reach US$36.8 Million by 2030

The global market for In-Vitro and In-Vivo Micro Electrode Arrays estimated at US$30.3 Million in the year 2024, is expected to reach US$36.8 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Multiwell MEA Type, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$24.6 Million by the end of the analysis period. Growth in the Single Well MEA Type segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.3 Million While China is Forecast to Grow at 6.3% CAGR

The In-Vitro and In-Vivo Micro Electrode Arrays market in the U.S. is estimated at US$8.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.3 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global In-Vitro and In-Vivo Micro Electrode Arrays Market - Key Trends & Drivers Summarized

Why Are Micro Electrode Arrays Critical to Advancing Neuroscience and Biomedical Research?

In-vitro and in-vivo micro electrode arrays (MEAs) are playing a transformative role in modern neuroscience and biomedical research by enabling high-resolution recording and stimulation of neural and cellular activity. These devices provide a powerful interface between biological tissues and electronic systems, allowing researchers to decode complex neural circuits, monitor disease progression, and test pharmacological responses in real time. In vitro MEAs are widely used in cell cultures, organotypic slices, and brain-on-chip models to study phenomena such as synaptic transmission, neurotoxicity, and drug efficacy, offering an ethical and efficient alternative to whole-animal experimentation. In vivo MEAs, on the other hand, are crucial for chronic implantation and live monitoring of brain activity in preclinical and clinical models, offering insights into conditions like epilepsy, Parkinson’s disease, and spinal cord injury. The ability to observe electrical patterns with millisecond precision and cellular-level resolution makes MEAs indispensable for understanding the dynamics of the nervous system, mapping brain regions, and refining neuroprosthetic development. As precision medicine gains momentum, MEAs are enabling the validation of gene therapies and neural interface technologies. Their versatility spans disciplines from neurobiology and pharmacology to tissue engineering and brain-computer interface research. With the rise of personalized and data-driven approaches in life sciences, micro electrode arrays serve as foundational tools for unlocking the complexities of cellular communication and neurophysiology.

How Are Technological Innovations Enhancing the Performance and Applications of MEAs?

Rapid advancements in materials science, microfabrication techniques, and computational processing are significantly expanding the capabilities of in-vitro and in-vivo micro electrode arrays. Modern MEAs are being fabricated with ultra-thin, flexible substrates such as polyimide, parylene, and graphene, which offer superior biocompatibility and mechanical conformity for chronic implantation. These flexible devices reduce tissue damage and inflammation while maintaining stable, long-term recordings. Innovations in electrode miniaturization and density have resulted in high-channel-count MEAs that can simultaneously record from thousands of sites, offering comprehensive spatial and temporal resolution across neural networks. Integration with optical sensors, microfluidics, and drug delivery components has led to the development of multifunctional platforms capable of simultaneous electrophysiology, imaging, and localized chemical stimulation. On the software side, machine learning algorithms and advanced signal processing tools are enabling real-time decoding of neural activity, facilitating more accurate interpretation and automation of data analysis. Wireless MEA systems are emerging to support untethered animal experiments, thereby preserving natural behaviors and reducing stress-related artifacts. Power efficiency and data transmission speeds have also improved, supporting continuous monitoring and closed-loop stimulation paradigms. These innovations are broadening the use of MEAs beyond traditional neuroscience into cardiac electrophysiology, organoid development, and bioelectronic medicine. As MEA technology continues to evolve, its precision, reliability, and adaptability are making it a cornerstone of next-generation bioelectronic and neuroengineering solutions.

How Do Research Objectives and Biological Models Influence MEA Design and Use?

The design and deployment of micro electrode arrays are highly dependent on the specific research objectives and the biological models being studied, necessitating a tailored approach for each application. In-vitro MEAs used for cell cultures or brain slices typically feature planar configurations with transparent substrates to facilitate simultaneous optical imaging and patch clamping. These systems are ideal for high-throughput screening of drug compounds, modeling neural development, and assessing neurotoxic effects in a controlled environment. Conversely, in-vivo MEAs are engineered for insertion into live tissue and must navigate complex anatomical structures while minimizing immune response. Designs range from single-shank probes targeting deep brain structures to multi-shank arrays that span cortical layers, allowing researchers to monitor diverse neural populations simultaneously. For applications involving freely moving animals, MEAs must be lightweight and robust enough to withstand physical activity, while maintaining high fidelity recordings. Chronic implant studies require stable electrode materials and protective coatings to ensure signal integrity over extended periods. Researchers studying motor control or seizure activity may integrate MEAs with behavioral tracking systems to correlate electrical signals with real-world actions. In regenerative medicine, MEAs are being used to monitor the functional integration of stem cell-derived neurons in host tissue, offering real-time validation of therapeutic efficacy. The diversity of experimental setups in academia, pharma, and clinical research continues to drive demand for modular, customizable MEA platforms that can adapt to various tissue types, scales, and analytical workflows. This demand for versatility and specificity is shaping the next wave of innovation in MEA design.

What Is Driving the Growth of the Global In-Vitro and In-Vivo Micro Electrode Arrays Market?

The growth in the in-vitro and in-vivo micro electrode arrays market is driven by a confluence of scientific, clinical, and technological factors that are reshaping the landscape of biomedical research and therapeutic development. One of the most influential drivers is the increasing global burden of neurological and neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, epilepsy, and multiple sclerosis, which is prompting an urgent need for advanced diagnostic tools and treatment monitoring methods. MEAs offer the unique capability to study disease mechanisms at the cellular and network levels, accelerating the discovery of new drug targets and biomarkers. In parallel, the surge in brain-machine interface research, including neuroprosthetics and cognitive enhancement technologies, is expanding the demand for high-resolution neural recording tools. Government and private sector funding for neuroscience and precision medicine is further catalyzing research that relies on MEA platforms for functional validation and real-time feedback. The rise of 3D cell cultures, brain organoids, and lab-on-chip technologies is opening new frontiers for in-vitro MEAs in drug testing and developmental biology. Academic institutions, biotech firms, and contract research organizations are all contributing to a rising volume of studies requiring reproducible, scalable, and high-throughput data acquisition, favoring MEAs over traditional electrophysiological techniques. Additionally, regulatory momentum behind non-animal testing methods is creating opportunities for MEAs to serve as ethical and efficient alternatives in pharmaceutical pipelines. As the push for personalized, data-intensive, and ethically sound research methodologies intensifies, the role of micro electrode arrays is set to expand significantly, positioning them as essential tools in the future of life sciences and neurotechnology.

SCOPE OF STUDY:

The report analyzes the In-Vitro and In-Vivo Micro Electrode Arrays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Multiwell MEA Type, Single Well MEA Type); Technology (In-vitro MEA Technology, In-vivo MEA Technology); Component (Hardware Component, Software Component); Application (Neuroscience Research Application, Cardiac Research Application, Drug Development / Toxicity Testing Application); End-Use (Pharmaceuticals Companies & CROs End-Use, Academic / Government & Other Research Labs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â